J-ALEX

一行要約

日本人 ALK 陽性 NSCLC における Alectinib (300 mg BID、日本承認用量) vs Crizotinib の phase III。PFS HR 0.34 (NE vs 10.2 mo) という圧倒的な efficacy 差を示し、中間解析で独立データモニタリング委員会が早期中止を勧告。ALEX (global) に先行して Alectinib 1L 標準の根拠を提供した日本発の pivotal trial。

試験デザイン

• 対象: ALK 陽性 NSCLC (IHC/FISH 確認)、化療 0-1 レジメン既治療 (Crizotinib 未治療)、ECOG PS 0-2、脳転移許容 (有症状は除外)、N=207 (1:1)、日本のみ
• 介入群 (n=103) : Alectinib 300 mg BID (日本承認用量 — global の 600 mg BID とは異なる)
• 対照群 (n=104) : Crizotinib 250 mg BID
• 層別化: 治療ライン (1L vs 2L)、ECOG PS (0-1 vs 2)、脳転移有無
• 主要評価項目: PFS (独立中央判定)
• 登録 ID: JapicCTI-132316

主要結果

• PFS (primary) : HR 0.34 (99.7% CI 0.17–0.71, p<0.0001)、median NE vs 10.2 mo — 中間解析 (66% events) で有意差到達、早期中止
• 1L subset: PFS HR 0.28 (NE vs 10.2 mo) — 未治療群で特に顕著
• ORR: 92% vs 79%
• Intracranial response: 脳転移ありの subset で CNS progression 率は Alectinib で著明に低い
• Grade ≥3 AE: Alectinib 26% vs Crizotinib 52%。Alectinib で忍容性が良好 (GI toxicity、visual disturbance が顕著に少ない)
• OS: 長期 follow-up でも両群ともに未成熟 (crossover および長い post-progression survival)

臨床的意義

• Alectinib 1L 標準の先行確立: 2016 年の ASCO 発表で世界的に注目を集め、ALEX (global) の結果発表 (2017) に先行して Alectinib 1L 標準の evidence を提示。日本では ALEX に先立ち Alectinib 1L が保険適用
• 用量の違い: 日本承認用量 (300 mg BID) は global (600 mg BID) の半量だが、HR 0.34 は ALEX の HR 0.47 よりも良好。体重差・pharmacokinetics の影響が議論されるが、direct comparison は不可能
• ALEX との相補性: J-ALEX (日本人、300 mg BID) と ALEX (global、600 mg BID) が independent に Alectinib 1L の優位性を確認したことで、evidence の robustness が確保
• ALK-TKI 世代間競争の起点: Crizotinib 1L 時代の終焉を告げ、Alectinib → Lorlatinib (CROWN) への世代進化の文脈を形成

Open Questions

• 300 mg vs 600 mg BID: 日本の 300 mg BID で十分な CNS penetration が得られるか、leptomeningeal disease での efficacy
• J-ALEX OS final: Crossover の影響を調整した OS benefit の評価
• Alectinib 耐性後の最適 sequential: J-ALEX cohort における ALK 耐性変異 spectrum (G1202R 等) と後続 Lorlatinib の efficacy

重要論文 Top 10

1. ★★★★★ Hida et al. Lancet 2017 — Primary publication — PFS HR 0.34、世界初の Alectinib vs Crizotinib
2. Hida et al. (final PFS) — Final PFS — 長期 follow-up で benefit 維持確認
3. ★★★★★ Peters et al. NEnglJMed 2017 (ALEX) — Global companion — Alectinib 600 mg BID、PFS HR 0.47
4. ★★★★ Seto et al. LancetOncol 2013 — Alectinib phase I/II in Japan — dose finding 300 mg BID
5. ★★★★★ Shaw et al. NEnglJMed 2020 (CROWN) — Lorlatinib 1L — 次世代 ALK-TKI

関連エンティティ・概念

• 薬剤: Alectinib / Crizotinib
• 関連試験: ALEX (global Alectinib 1L) / PROFILE-1014 (Crizotinib 1L) / CROWN (Lorlatinib 1L) / ASCEND-4 (Ceritinib 1L) / ALTA-1L (Brigatinib 1L)
• 関連遺伝子: ALK
• 関連概念: G1202R-solvent-front-resistance
• ドメイン: lung-cancer-treatment

関連論文

直近 30 件のみ表示中 (関連 32 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Brain metastasis

• Page et al. EurJCancer 2020 — Systemic treatment of brain metastases in non-small cell lung cancer

Clinical-NSCLC-ALK

• Lovly et al. AmSocClinOncolEducBook 2017 — Managing resistance to EFGR-and ALK-targeted therapies
• Novello et al. AnnOncol 2018 — Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung
• Lin et al. CancerDiscov 2017 — Targeting ALK Precision medicine takes on drug resistance
• Toyokawa et al. CancerMetastasisRev 2015 — Insights into brain metastasis in patients with ALK+ lung cancer is the brain truly a sanctuary
• Fukuda et al. CancerRes 2019 — Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK
• Hida et al. CancerSci 2018 — Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic
• Katayama et al. CancerSci 2018 — Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer
• Ando et al. Cancers 2020 — Brigatinib and alectinib for ALK rearrangement positive NSCLC with or without CNS metastasis
• Tanimoto et al. ClinCancerRes 2021 — Proteasome inhibition overcomes ALK-TKI resistance in ALK-RearrangedTP53-mutant NSCLC via noxa expression
• Watanabe et al. ClinLungCancer 2016 — Progression-free and overall survival of patients with ALK rearrangement-positive non-small cell lung cancer treated
• Asao et al. ClinLungCancer 2017 — Sequential use of anaplastic lymphoma kinase inhibitors in japanese patients with ALK-rearranged non-small-cell lung
• Ito et al. EurJCancer 2021 — Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma
• Tsao et al. IASLC 2016 — Atlas of ALK and ROS1 Testing in Lung Cancer Second Edition
• Ou et al. JClinOncol 2016 — Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer A phase II global study
• Tamura et al. JClinOncol 2017 — Three-year follow-up of an alectinib phase III study in ALK-positive non-small-cell lung cancer AF-001jp
• Camidge et al. JClinOncol 2020 — Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer second interim
• Ito et al. JThoracOncol 2017 — Sequential therapy with crizotinib and alectinib in ALK-rearranged non-small cell lung cancer-A multicenter
• Makimoto et al. JThoracOncol 2019 — Rapid acquisition of alectinib resistance in ALK-positive lung cancer with high tumor mutation burden
• Nishio et al. JThoracOncol 2021 — Brigatinib in japanese patients with ALK-positive NSCLC previously treated with alectinib and other tyrosine kinase
• Kiura et al. JpnJClinOncol 2018 — Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and
• Hida et al. Lancet 2017 — Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX) an open-label, randomised
• Gadgeel et al. LancetOncol 2014 — Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant
• Zhou et al. LancetRespirMed 2019 — Alectinib versus crizotinib in untreated asian patients with anaplastic lymphoma kinase-positive non-small-cell lung
• Nishio et al. LungCancer 2018 — Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive
• Nakagawa et al. LungCancer 2020 — Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive
• Peters et al. NEnglJMed 2017 — Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer
• Jahanzeb et al. Oncologist 2020 — Real-world treatment patterns and progression-free survival associated with anaplastic lymphoma kinase (ALK) tyrosine

Clinical-NSCLC-Driver-Other

• Jonna et al. ClinCancerRes 2019 — Detection of NRG1 gene fusions in solid tumors

Clinical-NSCLC-EGFR

• Asao et al. RespirInvestig 2019 — Resistance to molecularly targeted therapy in non-small-cell lung cancer